Category: car-nk

  • Nkarta leaps on early CAR-NK data in blood cancers

    Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be on to a winner with its natural kill (NK) cell therapy platform. The two phase 1 trials of the California biotech’s lead CAR-NK candidates showed that the therapies were able to induce complete responses in two groups […]

  • Gilead combs Shoreline for NK cell therapies in $2.3bn alliance

    Gilead Sciences’ cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off-the-shelf therapies for haematological cancers. The two companies will collaborate on the development of targeted NK cell and macrophage cells derived from induced pluripotent stem […]

  • Catamaran joins the CAR-NK fleet, raising $42m in first round

    Catamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its off-the-shelf natural killer (NK) cell therapies for cancer through early-stage development. The Cambridge, Massachusetts-based biotech is the latest player in the emerging field of chimeric antigen receptor (CAR) NK cell therapies, which unlike the current generation of […]